Shares of Quanterix Corporation (NASDAQ:QTRX – Get Free Report) have been given an average recommendation of “Hold” by the six research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $11.75.
A number of research firms recently issued reports on QTRX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Quanterix in a report on Saturday. Canaccord Genuity Group reissued a “hold” rating and set a $5.00 price target (down from $12.00) on shares of Quanterix in a report on Monday, August 11th.
Check Out Our Latest Research Report on QTRX
Institutional Inflows and Outflows
Quanterix Price Performance
Shares of NASDAQ:QTRX opened at $5.72 on Thursday. The stock has a market capitalization of $265.81 million, a price-to-earnings ratio of -3.14 and a beta of 1.07. The business’s fifty day moving average price is $5.23 and its two-hundred day moving average price is $5.48. Quanterix has a fifty-two week low of $4.05 and a fifty-two week high of $15.67.
Quanterix (NASDAQ:QTRX – Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.06). Quanterix had a negative net margin of 56.04% and a negative return on equity of 18.41%. The firm had revenue of $24.48 million for the quarter, compared to analyst estimates of $29.73 million. Quanterix has set its FY 2025 guidance at EPS. Research analysts expect that Quanterix will post -0.98 EPS for the current fiscal year.
Quanterix Company Profile
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.
Read More
- Five stocks we like better than Quanterix
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Tractor Supply Stock Looks Like a Buy-and-Hold Winner
- What is a Dividend King?
- 3 Stocks Well Below 52-Week Highs Poised for a Q4 Rebound
- What is the Euro STOXX 50 Index?
- Big Banks Are Setting the Tone as Earnings Season Kicks Off
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.
